ESR1 and breast cancer: Another study has evaluated 12,366 patients for either stromal or intratumoral CD8+ TILs and demonstrated no influence of intratumoral CD8+ TILs on BC-specific survival for ER+ BC, but an effect of stromal CD8+ TILs on survival for ER-HER2+ BCs15.